PhD Scientific Days 2020

Clinical Medicine III. Lectures

Elevated PD-L1 Protein Expression Predicts Poor Survival Outcomes in Patients with Malignant Pleural Mesothelioma: An International Multicenter Study

Előadó neve

Dr. Megyesfalvi, Zsolt

Előadó munkahelye

Department of Thoracic Surgery, Semmelweis University and National Institute of Oncology, Budapest

Előadó telefonszáma

+36204243934

Előadó e-mail címe

megyesfalvi.zsolt@semmelweis-univ.hu

Az előadás címe

Elevated PD-L1 Protein Expression Predicts Poor Survival Outcomes in Patients with Malignant Pleural Mesothelioma: An International Multicenter Study

Szerző(k) neve és munkahelye

Zsolt Megyesfalvi1,2,3; Thomas Klikovits3; Luka Brcic4; Marko Jakopovic5; Izidor Kern6; Katja Mohorcic6; Swen Seiwerth7; Mirjana Rajer6; Walter Klepetko3; Balázs Hegedüs8; Ferenc Rényi-Vámos1,9; Viktória László2,3; Mir Alireza Hoda3; Martin Filipits10; Balázs Döme1,2,3

1- Department of Thoracic Surgery, Semmelweis University and National Institute of Oncology, Budapest, Hungary
2- Department of Tumor Biology, National Korányi Institute of Pulmonology, Budapest, Hungary
3- Division of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Center, Medical University of Vienna, Austria
4- Institute of Pathology, Medical University of Graz, Graz, Austria
5- University of Zagreb School of Medicine, Department for Respiratory Diseases Jordanovac, University Hospital Center Zagreb, Croatia
6- Department of Pathology, University Clinic Golnik, Golnik, Slovenia
7- Departments of Pharmacology and Pathology, Medical Faculty University of Zagreb, Croatia
8- Translational Laboratory, Department of Thoracic Surgery, Ruhrlandklinik, University Clinic Essen, Essen, Germany
9- Department of Thoracic Surgery, National Korányi Institute of Pulmonology, Budapest, Hungary
10- Institute of Cancer Research and Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria

Szekció

Clinical Medicine III. Lectures

Language of the presentation

English

Section, first choice

Pathology and Oncology

Section, second choice

Clinical Medicine

Összefoglaló szövege

Introduction: The PD-1/PD-L1 immune-checkpoint blockade is a promising new therapeutic strategy in cancer patients, yet the expression pattern and prognostic significance of both PD-L1 and PD-1 are still partly controversial in human malignant pleural mesothelioma (MPM).

Aims: Our study aimed to investigate the expression of PD-L1/PD-1 in the tumor samples of MPM patients and to analyze potential correlations with clinicopathological parameters.

Method: Diagnostic biopsies of 203 MPM patients were collected from five Central European centers. The formalin-fixed paraffin-embedded samples were evaluated for PD-L1 and PD-1 expression on tumor cells and tumor-infiltrating lymphocytes by immunohistochemistry, and their prognostic significance was examined. To assess the PD-L1 and PD-1 expression pattern threshold value of 10% was used regardless of intensity.

Results: High (>10%) tumor cell PD-L1 expression was found in 8% of samples and high (>10%) tumor-infiltrating lymphocyte PD-1 expression in 24%. No significant associations were found between PD-L1/PD-1 expression and clinicopathological variables (patients’ age, gender, histological subtype, stage and treatment modality). As for their prognostic relevance, the median overall survival time of patients with high (>10%) PD-L1 expression on tumor cells was significantly shorter compared to those with lower PD-L1 expression (6.2 vs. 15.1 months, respectively; p<0.001). Notably, high PD-L1 expression (>10%) proved to be an independent prognostic factor in the multivariate Cox regression analysis as well regardless of histology (hazard ratio HR] 2.711; 95% confidence interval [CI] 1.201 to 6.118; p=0.016). No significant difference was found in overall survival regarding PD-1 expression (p=0.481).

Conclusion: The results of this multicenter study demonstrate that high (>10%) PD-L1 expression on tumor cells is an independent prognostic factor for worse survival outcomes in MPM. Furthermore, this is the first report comprehensively evaluating the expression and prognostic value of PD-1 on tumor-infiltrating lymphocytes.

Additional Information

Supervisor: Balázs Döme;
E-mail address: balazs.dome@meduniwien.ac.at.

Bemutatás módja

Szóbeli

Kind

Szabad

Status

elfogadva

Accepted presentation method

szóbeli

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

4071

Start

11:40

End

11:55

Authors (legacy)

Zsolt Megyesfalvi1,2,3; Thomas Klikovits3; Luka Brcic4; Marko Jakopovic5; Izidor Kern6; Katja Mohorcic6; Swen Seiwerth7; Mirjana Rajer6; Walter Klepetko3; Balázs Hegedüs8; Ferenc Rényi-Vámos1,9; Viktória László2,3; Mir Alireza Hoda3; Martin Filipits10; Balázs Döme1,2,3

1- Department of Thoracic Surgery, Semmelweis University and National Institute of Oncology, Budapest, Hungary
2- Department of Tumor Biology, National Korányi Institute of Pulmonology, Budapest, Hungary
3- Division of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Center, Medical University of Vienna, Austria
4- Institute of Pathology, Medical University of Graz, Graz, Austria
5- University of Zagreb School of Medicine, Department for Respiratory Diseases Jordanovac, University Hospital Center Zagreb, Croatia
6- Department of Pathology, University Clinic Golnik, Golnik, Slovenia
7- Departments of Pharmacology and Pathology, Medical Faculty University of Zagreb, Croatia
8- Translational Laboratory, Department of Thoracic Surgery, Ruhrlandklinik, University Clinic Essen, Essen, Germany
9- Department of Thoracic Surgery, National Korányi Institute of Pulmonology, Budapest, Hungary
10- Institute of Cancer Research and Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria